Karyotypic "state" as a potential determinant for anticancer drug discovery

Proceedings of the National Academy of Sciences of the United States of America

Volumn 102, Issue 8, 2005, Pages 2964-2969

  Roschke, Anna V ^a   Lababidi, Samir ^a   Tonon, Giovanni ^a   Gehlhaus, Kristen S ^a   Bussey, Kimberly ^a   Weinstein, John N ^a   Kirsch, Ilan R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; Chromosome; Karyotypic complexity; NCI 60

Indexed keywords

2 (2,4 DINITROPHENYL) 2 METHYLHYDRAZONE; 2 PROPENAMIDE 3 (1,2,3,4 TETRAHYDRO 6 METHYL 2,4 DIOXO 5 PYRIMIDINYL) DERIVATIVE; 8 QUINOLINECARBOXALDEHYDE; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BENZODITHIOPHENE 4,8 DIONE DERIVATIVE; BUSULFAN; CAMPTOTHECIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; COMBRETASTATIN; CYTARABINE; CYTOCHALASIN DERIVATIVE; DACTINOMYCIN; DAUNORUBICIN; ELLIPTICINE; ELLIPTINIUM; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; FUCHSINE; GELDANAMYCIN; GEMCITABINE; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; OLIVACINIUM; RIFAMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER SCREENING; CARCINOMA; CHROMOSOME ANALYSIS; CYTOTOXICITY; DRUG DETERMINATION; GENETIC DISORDER; GENOMIC INSTABILITY; KARYOTYPE; KARYOTYPING; PRIORITY JOURNAL;

CHROMOSOME ABERRATIONS; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; KARYOTYPING;

EID: 14544308364     PISSN: 00278424     EISSN: None     Source Type: Journal    
DOI: 10.1073/pnas.0405578102     Document Type: Article

References (33)

1. Druker, B. J. (2002) Cancer Cell 1, 31-36.
2. Sawyers, C. L. (2003) Genes Dev. 17, 2998-3010.
3. Junicke, H., Hart, J. R., Kisko, J., Glebov, O., Kirsch, I. R. & Barton, J. K. (2003) Proc. Natl. Acad. Sci. USA 100, 3737-3742.
4. Chen, W. D., Eshleman, J. R., Aminoshariae, M. R., Ma, A. H., Veloso, N., Markowjtz, S. D., Sedwick, W. D. & Veigl, M. L. (2000) J. Natl. Cancer Inst. 92, 480-485.
5. Yunis, J. J. (1983) Science 221, 227-236.
6. Mitelman, F., Johansson, B., Mandahl, N. & Mertens, F. (1997) Cancer Genet. Cytogenet. 95, 1-8.
7. Ried, T., Heselmeyer-Haddad, K., Blegen, H., Schröck, E. & Auer, G. (1999) Genes Chromosomes Cancer 25, 195-204.
8. Bardi, G., Johansson, B., Pandis, N., Bak-Jensen, E., Orndal, C., Heim, S., Mandahl, N., Andren-Sandberg, A. & Mitelman, F. (1993) Cancer 71, 306-314.
9. Johansson, B., Bardi, G., Pandis, N., Gorunova, L., Backman, P. L., Mandahl, N., Dawiskiba, S., Andren-Sandberg, A., Heim, S. & Mitelman, F. (1994) Int. J. Cancer 58, 8-13.
10. Pandis, N., Idvall, I., Bardi, G., Jin, Y., Gorunova, L., Mertens, F., Olsson, H., Ingvar, C, Beroukas, K., Mitelman, F. & Heim, S. (1996) Int. J. Cancer 66, 191-196.
11. Bardi, G., Fenger, C., Johansson, B., Mitelman, F. & Heim, S. (2004)J. Clin. Oncol. 22, 2623-2634.
12. Shoemaker, R. H., Monks, A., Alley, M. C., Scudiero, D. A., Fine, D. L., McLemore, T. L., Abbott, B. J., Paull, K. D., Mayo, J. G. & Boyd, M. R. (1988) Prog. Clin. Biol. Res. 276, 265-286.
13. Stinson, S. F., Alley, M. C., Kopp, W. C., Fiebig, H. H., Mullendore, L. A., Pittman, A. F., Kenney, S., Keller, J. & Boyd, M. R. (1992) Anticancer Res. 12, 1035-1053.
14. Monks, A., Scudiero, D. A., Johnson, G. S., Paull, K. D. & Sausville, E. A. (1997) Anticancer Drug. Des. 12, 533-541.
15. Weinstein, J. N., Myers, T. G., O'Connor, P. M., Friend, S. H., Fornace, A. J., Jr., Kohn, K. W., Fojo, T., Bates, S. E., Rubinstein, L. V., Anderson, N. L., et al. (1997) Science 275, 343-349.
16. Roschke, A. V., Tonon, G., Gehlhaus, K. S., McTyre, N., Bussey, K. J., Lababidi, S., Scudiero, D. A., Weinstein, J. N. & Kirsch, I. R. (2003) Cancer Res. 63, 8634-8647.
17. Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., et al. (2000) Nat. Genet. 24, 236-244.
18. ISCN (1995) An International System for Human Cytogenetic Nomenclature (Karger, Basel).
19. Chernick, M. R. (1999) Bootstrap Methods: A Practitioner's Guide (Wiley, New York).
20. Goldie, J. H. & Coldman, A. J. (1998) Drug Resistance in Cancer: Mechanisms and Models (Cambridge Univ. Press, Cambridge, U.K.).
21. Snijders, A. M., Fridlyand, J., Mans, D. A., Segraves, R., Jain, A. N., Pinkel, D. & Albertson, D. G. (2003) Oncogene 22, 4370-4379.
22. Cooper, J. A. (1987) J. Cell Biol. 105, 1473-1478.
23. Rampal, A. L., Pinkofsky, H. B. & Jung, C. Y. (1980) Biochemistry 19, 679-683.
24. Shi, L. M., Myers, T. G., Fan, Y., O'Connor, P. M., Paull, K. D., Friend, S. H. & Weinstein, J. N. (1998) Mol. Pharmacol. 53, 241-251.
25. Peng, Y., Li, C., Chen, L., Sebti, S. & Chen, J. (2003) Oncogene 22, 4478-4487.
26. Kohn, K. W., Waring, M. J., Glaubiger, D. & Friedman, C. A. (1975) Cancer Res. 35, 71-76.
27. Auclair, C. (1987) Arch. Biochem. Biophys. 259, 1-14.
28. Cirla, A. & Mann, J. (2003) Nat. Prod. Rep. 20, 558-564.
29. Thorpe, P. E. (2004) Clin. Cancer Res. 10, 415-427.
30. Holwell, S. E., Cooper, P. A., Grosios, K., Lippert, J. W., 3rd, Pettit, G. R., Shnyder, S. D. & Bibby, M. C. (2002) Anticancer Res. 22, 707-711.
31. Bayes, M., Rabasseda, X. & Prous, J. R. (2003) Methods Find. Exp. Clin. Pharmacol. 25, 483-506.
32. Marshall, J. L., Rizvi, N., Kauh, J., Dahut, W., Figuera, M., Kang, M. H., Figg, W. D., Wainer, I., Chaissang, C., Li, M. Z. & Hawkins, M. J. (2002) J. Exp. Ther. Oncol. 2, 325-332.
33. Sandor, V., Bakke, S., Robey, R. W., Kang, M. H., Blagosklonny, M. V., Bender, J., Brooks, R., Piekarz, R. L., Tucker, E., Figg, W. D., et al. (2002) Clin. Cancer Res. 8, 718-728.